Merck Narrows 2026 Sales Guidance, Raises Profit Outlook
- Reported first-quarter 2026 financial results on April 30, 2026, that exceeded analyst expectations, driven by strong demand for its cancer immunotherapy Keytruda and several newer products.
- The company reported revenue of $16.29 billion for the first quarter, surpassing the $15.82 billion expected by analysts.
- Despite beating estimates on an adjusted basis, Merck recorded a net loss of $4.24 billion, or $1.72 per share, for the quarter.
Merck & Co. Reported first-quarter 2026 financial results on April 30, 2026, that exceeded analyst expectations, driven by strong demand for its cancer immunotherapy Keytruda and several newer products. Alongside the quarterly results, the pharmaceutical company raised its adjusted profit outlook and narrowed its sales guidance for the full year.
The company reported revenue of $16.29 billion for the first quarter, surpassing the $15.82 billion expected by analysts. On an adjusted basis, Merck posted a loss of $1.28 per share, which was better than the $1.51 loss per share anticipated by Wall Street.
Despite beating estimates on an adjusted basis, Merck recorded a net loss of $4.24 billion, or $1.72 per share, for the quarter. This represents a significant shift from the same period in the previous year, when the company reported net income of $5.08 billion, or $2.01 per share.
The company attributed the quarterly net loss to a $3.62 per share charge related to its acquisition of Cidara Therapeutics, a biotechnology firm focused on the development of a drug for flu prevention.
Updated 2026 Financial Outlook
Merck narrowed and raised its worldwide sales guidance for the full year of 2026. The company now expects sales to fall between $65.8 billion and $67 billion, raising the low end of that range from a previous estimate of $65.5 billion.
The company also adjusted its expectations for earnings per share. Merck now anticipates adjusted earnings to be between $5.04 and $5.16 per share, an increase from the previous outlook of $5 to $5.15 per share.
Management indicated that the revised outlook was influenced by foreign exchange tailwinds and the performance of the underlying business.
The updated financial guidance does not currently reflect any potential impact from the proposed acquisition of Terns Pharmaceuticals, Inc.
Strategic Positioning and Market Pressures
The company’s recent financial activity and acquisition strategy are part of an effort to offset upcoming generic competition for several key products. Merck expects to face generic competition for its Type 2 diabetes medications, Januvia and Janumet, later in 2026.
the company is preparing for the loss of exclusivity for Keytruda, which is expected to occur in 2028. The strong demand for Keytruda remains a primary driver of current revenue growth as the company seeks to diversify its portfolio through acquisitions and the launch of new products.